1. Biologic Therapy for Ulcerative Colitis.
- Author
-
Bhattacharya A and Osterman MT
- Subjects
- Acute Disease, Adalimumab economics, Adalimumab therapeutic use, Antibodies, Monoclonal economics, Antibodies, Monoclonal therapeutic use, Antibodies, Monoclonal, Humanized economics, Antibodies, Monoclonal, Humanized therapeutic use, Biological Products economics, Colitis, Ulcerative economics, Cost Savings, Drug Monitoring, Health Care Costs, Humans, Infliximab economics, Severity of Illness Index, Treatment Outcome, Ustekinumab economics, Ustekinumab therapeutic use, Biological Products therapeutic use, Biological Therapy economics, Colitis, Ulcerative drug therapy, Infliximab therapeutic use
- Abstract
Five biologics are approved for the treatment of ulcerative colitis (UC): infliximab, adalimumab, golimumab, vedolizumab, and ustekinumab. These drugs have varying levels of efficacy and are recommended as first-line treatment of moderate to severe UC. There has been only 1 head-to-head trial comparing the efficacy of the biologics, adalimumab and vedolizumab, which has important implications for management. Therapeutic drug monitoring of biologics, especially anti-TNF alpha agents, may improve the long-term efficacy of these agents. The future of treatment may include personalization of medications, based on patient-specific and disease-specific characteristics as well as biomarkers, along with appropriate therapeutic drug monitoring., Competing Interests: Disclosure A. Bhattacharya: none. M.T. Osterman: advisory board consultant for AbbVie, Elan, Janssen, Lycera, Merck, Pfizer, Takeda, and UCB; research grant support from UCB., (Copyright © 2020 Elsevier Inc. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF